BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15969989)

  • 1. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
    Salama JK; Haraf DJ; Stenson K; Milano MT; Witt ME; Vokes EE
    Cancer J; 2005; 11(2):140-6. PubMed ID: 15969989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
    Brockstein B; Haraf DJ; Stenson K; Sulzen L; Witt ME; Weichselbaum RW; Vokes EE
    Ann Oncol; 2000 Jun; 11(6):721-8. PubMed ID: 10942062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
    Seiwert TY; Haraf DJ; Cohen EE; Stenson K; Witt ME; Dekker A; Kocherginsky M; Weichselbaum RR; Chen HX; Vokes EE
    J Clin Oncol; 2008 Apr; 26(10):1732-41. PubMed ID: 18375903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
    Spencer S; Wheeler R; Peters G; Meredith R; Beenken S; Nabel L; Wooten A; Soong SJ; Salter M
    Head Neck; 2003 Feb; 25(2):118-22. PubMed ID: 12509794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
    Brockstein B; Haraf DJ; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman SM; Ratain MJ; Sulzen L; Klepsch A; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1998 Feb; 16(2):735-44. PubMed ID: 9469365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
    Haraf DJ; Kies M; Rademaker AW; Stenson K; Mittal B; Pelzer H; Wenig B; Witt ME; Sulzen L; Weichselbaum RR; Vokes EE
    J Clin Oncol; 1999 Feb; 17(2):638-44. PubMed ID: 10080609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
    Milano MT; Haraf DJ; Stenson KM; Witt ME; Eng C; Mittal BB; Argiris A; Pelzer H; Kozloff MF; Vokes EE
    Clin Cancer Res; 2004 Aug; 10(15):4922-32. PubMed ID: 15297392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
    Vokes EE; Panje WR; Schilsky RL; Mick R; Awan AM; Moran WJ; Goldman MD; Tybor AG; Weichselbaum RR
    J Clin Oncol; 1989 Jun; 7(6):761-8. PubMed ID: 2715806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
    Kies MS; Haraf DJ; Rosen F; Stenson K; List M; Brockstein B; Chung T; Mittal BB; Pelzer H; Portugal L; Rademaker A; Weichselbaum R; Vokes EE
    J Clin Oncol; 2001 Apr; 19(7):1961-9. PubMed ID: 11283128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
    Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
    Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
    Vokes EE; Moormeier JA; Ratain MJ; Egorin MJ; Haraf DJ; Mick R; Weichselbaum RR
    Cancer Chemother Pharmacol; 1992; 29(3):178-84. PubMed ID: 1733549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
    Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
    J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
    Rosen FR; Haraf DJ; Kies MS; Stenson K; Portugal L; List MA; Brockstein BE; Mittal BB; Rademaker AW; Witt ME; Pelzer H; Weichselbaum RR; Vokes EE
    Clin Cancer Res; 2003 May; 9(5):1689-97. PubMed ID: 12738722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
    Mehta VK; Cho C; Ford JM; Jambalos C; Poen J; Koong A; Lin A; Bastidas JA; Young H; Dunphy EP; Fisher G
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):132-7. PubMed ID: 12504045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
    Salama JK; Vokes EE; Chmura SJ; Milano MT; Kao J; Stenson KM; Witt ME; Haraf DJ
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):382-91. PubMed ID: 16213104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.
    Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Ferreli L; Camboni P; Lusso MR; Mocci M; Madeddu C; Mura L; Mudu MC; Proto E; Tore G; Mura M; Macciò A; Ferreli A; Amichetti M
    Oncol Rep; 2003; 10(3):759-66. PubMed ID: 12684655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
    Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.